Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + DRd in Newly Diagnosed Multiple Myeloma
NCT04782687Phase 2Active, not recruiting
- Sponsor
- US Oncology Network
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by US Oncology Network. Started Sep 2021; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04782687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782687.